Nanopharmaceuticals to target antifilarials: A comprehensive review

Expert Opinion on Drug Delivery

Volumn 10, Issue 5, 2013, Pages 665-678

  Ali, Mohammad ^a   Afzal, Mohammad ^b   Bhattacharya, Shailja Misra ^c   Ahmad, Farhan Jalees ^d   Dinda, Amit Kumar ^e  

^a HAMDARD UNIVERSITY   (India)

^b Ayurvedic Research   (India)

^c CENTRAL DRUG RESEARCH INSTITUTE   (India)

^d ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^e HAMDARD UNIVERSITY   (India)

Author keywords

Antifilarial drug; Drug delivery system; Liposome; Lymphatic filariasis; Microfilaria; Nanoparticle

Indexed keywords

ANTIFILARIAL AGENT; DOXYCYCLINE; MACROGOL 2000; RIFAMPICIN; SOLID LIPID NANOPARTICLE; TETRACYCLINE;

ANTHELMINTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED DRUG RELEASE; DRUG BIOAVAILABILITY; DRUG DEGRADATION; DRUG HALF LIFE; DRUG SOLUBILITY; LIPOSOMAL DELIVERY; NANOPHARMACEUTICS; NANOTECHNOLOGY; NONHUMAN; PARTICLE SIZE;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; ELEPHANTIASIS, FILARIAL; FILARICIDES; FILARIOIDEA; HUMANS; LIPOSOMES; NANOPARTICLES; WOLBACHIA;

EID: 84876540971     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2013.771630     Document Type: Article

References (76)

1. WHO. Global programme to eliminate lymphatic filariasis. Weekly Epidemiol Rec 2009;437-44
2. Gyapong JO, Kumaraswami V, Biswas G, et al. Treatment strategies underpinning the global programme to eliminate lymphatic filariasis. Expert Opin Pharmacother 2005;6:179-200 (Pubitemid 40305333)
3. World Health Organization Global Programme to Eliminate Lymphatic Filariasis. Progress report for 2004. Weekly Epidemiol Rec 2005;80202-12
4. World Health Organization Global Programme to Eliminate Lymphatic Filariasis. Progress report on mass drug administrations in 2005. Weekly Epidemiol Rec 2006;22:221-32
5. World Health Organization Global Programme to Eliminate Lymphatic Filariasis. Progress report on mass drug administration in 2006. Weekly Epidemiol Rec 2007;82:361-80
6. World Health Organization Global Programme to Eliminate Lymphatic Filariasis. Progress report on mass drug administration in 2007. Weekly Epidemiol Rec 2008;83:333-48
7. Silva ND. Global elimination of lymphatic filariasis: Addressing the public health problem. PLoS Negl Trop Dis 2010;4:34-45
8. Marcato PD, Dura'n N. New aspects of nanopharmaceutical delivery systems. J Nanosci Nanotechnol 2008;8:1-14
9. Sahni JK, Baboota S, Ali J, et al. Promising role of nanopharmaceuticals in drug delivery. Pharma Times 2011;10
10. Bawarski WE, Chidlowsky E, Bharali DJ, et al. Emerging nanopharmaceuticals. Nanomedicine 2008;4:273-82
11. Horstkotte E, Odoerfer KI. Towards improved therapies using nanopharmaceuticals: Recent patents on pharmaceutical nanoformulations. Recent Pat Food Nutr Agric 2012;4(3):220-44
12. Patlak M. Nanotechnology takes a new look at old drugs. J Natl Cancer Inst 2010;23:1753-5
13. Sundar S. Liposomal amphotericin B. Lancet 2001;357:801-2
14. Singh PK, Ajay A, Kushwaha S, et al. Towards novel antifilarial drugs: Challenges and recent developments. Future Med Chem 2010;2(2):251-83
15. Hawley AE, Davis SS, Illum L. Targeting of colloids to lymph nodes: Influence of lymphatic physiology and colloidal characteristics. Adv Drug Deliv Rev 1995;17(1):129-48
16. Shieh MJ, Hsu CH, Huang LY, et al. Reversal of doxorubicin-resistance by multifunctional nanoparticles in MCF-7/ADR cells. J Control Release 2011;152:418-25
17. Li PY, Lai PS, Hung WC, Syu WJ. Poly (L-lactide)-vitamin E TPGS nanoparticles enhanced the cytotoxicity of doxorubicin in drug-resistant MCF-7 breast cancer cells. Biomacromolecules 2010;11(10):2576-82
18. Wang X, Li J, Wang Y, et al. A folate receptor-targeting nanoparticle minimizes drug resistance in a human cancer model. ACS Nano 2011;23:6184-94
19. Vlerken LE, Amiji MM. Multi-functional polymeric nanoparticles for tumour-targeted drug delivery. Expert Opin Drug Deliv 2006;3:205-16 (Pubitemid 43338092)
20. Singh SK, Goswami K, Sharma RD, et al. Novel microfilaricidal activity of nanosilver. Int J Nanomedicine 2012;7:1023-30
21. Ramyadevi J, Jeyasubramanian K, Marikani A, et al. Copper nanoparticles synthesized by polyol process used to control hematophagous parasites. Parasitol Res 2011;5:56-67
22. Salunkhe RB, Patil SV, Patil CD, Salunke BK. Larvacidal potential of silver nanoparticles synthesized using fungus Cochliobolus lunatus against Aedes aegypti and Anopheles stephensi Liston. Parasitol Res 2011;109:823-31
23. Pavel B. Polymer-based nanostructures: Medical applications. Royal Society of Chemistry, Cambridge; 2010
24. Wilczewska AZ, Niemirowicz K, Markiewicz KH, et al. Nanoparticles as drug delivery systems. Pharmacol Rep 2012;64(5):1020-37
25. Wertheimer AI, Santella TM, Finestone AJ, et al. Drug Delivery Systems improve pharmaceutical profile and facilitate medication adherence. Adv Ther 2010;6:559-77
26. Lu Y, Chen SC. Micro and nano-fabrication of biodegradable polymers for drug delivery. Adv Drug Deliv Rev 2004;56:1621-33 (Pubitemid 39177692)
27. Owais M, Misra-bhattacharya S, Haq W, Gupta CM. Immunomodulator tuftsin augments antifilarial activity of diethylcarbamazine against experimental Brugian Filariasis. J Drug Target 2003;11:247-51 (Pubitemid 37361971)
28. Bajpai P, Vedi S, Owais M, et al. Use of liposomized tetracycline in elimination of Wolbachia endobacterium of human lymphatic filariid Brugia malayi in a rodent model. J Drug Target 2005;13:375-81 (Pubitemid 41683991)
29. Dangi A, Dwivedi V, Vedi S, et al. Improvement in the antifilarial efficacy of doxycycline and rifampicin by combination therapy and drug delivery approach. J Drug Target 2010;18(5):343-50
30. Oussoren C, Storm G. Liposomes to target the lymphatics by subcutaneous administration. Adv Drug Deliv Rev 2001;50:143-56 (Pubitemid 32727280)
31. Oussoren C, Storm G. Subcutaneous administration of liposomes for lymphatic targeting. Adv Drug Deliv Rev 1997;7:227-40 (Pubitemid 27327152)
32. Oussoren C, Zuidema J, Crommelin DJA, et al. Lymphatic uptake and biodistribution of liposomes after subcutaneous injection-II, Influence of liposomal size, lipid composition and lipid dose. Biochim Biophys Acta 1997;4:261-72 (Pubitemid 27376453)
33. Immordino ML, Dosio F, Cattel L. Stealth liposomes: Review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine 2006;1(3):297-315 Biointerphases 2012;4:903-10
34. Specht S, Wanji S. New insights into the biology of filarial infections. J Helminthol 2009;83:199-202
35. Muller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery-A review of the state of the art. Eur J Pharm Biopharm 2000;50(1):161-77 (Pubitemid 30326695)
36. Uner M, Yener G. Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. Int J Nanomedicine 2007;2(3):289-300 (Pubitemid 350047774)
37. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev 2001;47:65-81 (Pubitemid 32209233)
38. Gupta Y, Jain A, Jain SK. Transferrin-conjugated solid lipid nanoparticles for enhanced delivery of quinine dihydrochloride to the brain. J Pharm and Pharmacol 2007;59:935-40 (Pubitemid 47051073)
39. Olbrich C, Gebner A, Kayser O, et al. Lipid-drug conjugate (LDC) nanoparticles as novel carrier system for the hydrophilic antitrypanosomal drug diminazene diaceturate. J Drug Target 2002;10:387-96
40. Ottesen EA. Immunopathology of lymphatic filariasis in man. Semin Immunopathol 1980;2:373-85 (Pubitemid 10089632)
41. Nitin G, Chaubal MD, Gautam M, et al. Dance of Live Adult Filarial Worms Is a Reliable Sign of Scrotal Filarial Infection. J Ultrasound Med 2003;22:765-9
42. Lu B, Xiong SB, Yang H, et al. Solid lipid nanoparticles of mitoxantrone for local injection against breast cancer and its lymph node metastases. Eur J Pharm Sci 2006;4:86-95
43. Lu B, Xiong B, Yang H, et al. Mitoxantrone-loaded BSA nanospheres and chitosan nanospheres for local injection against breast cancer and its lymph node metastases II:tissue distribution and pharmacodynamics. Int J Pharm 2006;2:168-74 (Pubitemid 41820410)
44. Dutt M, Khuller GK. Therapeutic efficacy of PLGA encapsulated antitubercular drug against mycobacterium tuberculosis infection induced in mice. Antimicrobe Agent 2001;45:363-9
45. William B, Liechty WB, David R, et al. Polymers for Drug Delivery Systems. Annu Rev Chem Bio Eng 2010;1:149-73
46. Utreja P, Jain S, Tiwary AK. Novel drug delivery systems for sustained and targeted delivery of anti- cancer drugs: Current status and future prospects. Curr Drug Deliv 2010;7(2):152-61
47. Date AA, Joshi MD, Patravale VB. Parasitic diseases: Liposomes and polymeric nanoparticles versus lipid nanoparticles. Adv Drug Deliv Rev 2007;10:505-21 (Pubitemid 47259228)
48. Romero EL, Morill MJ. Drug delivery systems against leishmaniasis Still an open question. Expert Opin Drug Deliv 2008;5(7):805-82
49. Santos-Magalhaes NS, Mosqueira VC. Nanotechnology applied to the treatment of malaria. Adv Drug Deliv Rev 2010;62:560-75
50. Xie Y, Bagby TR, Cohen MS, Forrest ML. Drug delivery to the lymphatic system: Importance in future cancer diagnosis and therapies. Expert Opin Drug Deliv 2009;6(8):785-92
51. Mahmud A, Xiong X, Montazeri H, et al. Polymeric micelles for drug targeting. J Drug Target 2007;15:553-84 (Pubitemid 350031081)
52. Gaspar R, Pre'at V, Opperdoes FR. Macrophage activation by polymeric nanoparticles of polyalkylcyanoacrylates: Activity against intracellular Leishmania donovani associated with hydrogen peroxide production. Pharm Res 1992;9(6):782-7
53. Albanese A, Tang PS, Chan WCW. The Effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu Rev Biomed Eng 2012;14:1-16
54. Reddy ST, Vlies AJ, Simeoni E. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat Biotechnol 2007;25:1159-64 (Pubitemid 47538111)
55. Nishioka Y, Yoshino H. Lymphatic targeting with nanoparticulate system. Adv Drug Deliv Rev 2001;23:55-64 (Pubitemid 32209232)
56. Saraf S, Ghosh A, Kaur CD, Saraf S. Novel modified nanosystems based lymphatic targeting. J Nanosci Nanotechnol 2011;1:60-74
57. Luo G, Yu X, Jin C, et al. LyP-1-conjugated nanoparticles for targeting drug delivery to lymphatic metastatic tumors. Int J Pharm 2010;385(1-2):150-6
58. Hauff P, Reinhard M, Briel A, et al. Molecular targeting of lymph nodes with L-selectin ligand-specific US contrast agent: A feasibility study in mice and dogs. Radiology 2004;231:667-73 (Pubitemid 38668081)
59. Kaur CD, Nahar M, Jain NK. Lymphatic targeting of zidovudine using surface-engineered liposomes. J Drug Target 2008;16:798-805
60. Ikehara Y, Niwa T, Biao LA. Carbohydrate recognition-based drug delivery and controlled release system using intraperitoneal macrophages as a cellular vehicle. Cancer Res 1999;2:29-38
61. Zhang H, Ma Y, Sun X. Recent developments in carbohydrate-decorated targeted drug/gene delivery. Med Res Rev 2003;4:495-508
62. Proft T, Baker EN. Pili in gram-negative and gram-positive bacteria - structure, assembly and their role in disease. Cell Mol Life Sci 2009;4:613-35
63. Kaminskas LM, Kota J, McLeod VM, et al. PEGylation of polylysine dendrimers improves absorption and lymphatic targeting following SC administration in rats. J Control Release 2009;140:108-16
64. Donald E, Nicholas A, Peppas A. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 2006;307:93-102
65. Banerjee SS, Aher N, Patil R, et al. Poly (ethylene glycol)-prodrug conjugates: Concept, design and applications. J Drug Deliv 2012;10:123-39
66. Fundaro A, Cavalli R, Bargoni A, et al. Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: pharmacokinetics and tissue distribution after iv administration to rats. Pharm Res 2000;42:337-43
67. Ami M, Krunal S, Hejal P, et al. Advancements in controlled release gastroretentive drug delivery system: A review. J Drug Deliv Ther 2012;2(3):34-41
68. Uhrich KE. Polymeric systems for controlled drug release. Chem Rev 1999;99:3181-98 (Pubitemid 129583051)
69. Biondi M, Ungaro F, Quaglia F. Controlled drug delivery in tissue engineering. Adv Drug Deliv Rev 2008;60(2):229-42 (Pubitemid 350236401)
70. Guerra-caceres JG, Bryceson ADM, Quakyi I, et al. Studies on the mechanisms of adverse reactions produced by diethyl carbamazine in patients with onchocerciasis- Mazzotti reaction. Parasite immunol 1980;2:121-31 (Pubitemid 11159554)
71. Bassi P, Kaur G. pH modulation: A mechanism to obtain pH-independent drug release. Expert Opin Drug Deliv 2010;7:845-57
72. Bikram M, West JL. Thermo-responsive systems for controlled drug delivery. Expert Opin Drug Deliv 2008;5:1077-91
73. Bawa P, Pillay V, Choonara YE. Stimuli-responsive polymers and their applications in drug delivery. Biomed Mater 2009;4:234-45
74. Morishita M, Lowman AM, Takayama K, et al. Elucidation of the mechanism of incorporation of insulin in controlled release systems based on complexation polymers. J Control Release 2002;81:25-32 (Pubitemid 34454846)
75. Cuong NV, Hsieh MF. Molecular targeting of liposomal nano-particles to lymphatic system. Curr Cancer Drug Targets 2011;11(2):147-55
76. Shin SB, Cho HY, Kim DD, et al. Preparation and evaluation of tacrolimus-loaded nanoparticles for lymphatic delivery. Eur J Pharm Biopharm 2010;74:164-71